Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Declines By 17.4%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 54,300 shares, a drop of 17.4% from the January 31st total of 65,700 shares. Currently, 3.9% of the company’s stock are short sold. Based on an average daily volume of 24,500 shares, the days-to-cover ratio is presently 2.2 days.

Alaunos Therapeutics Stock Performance

TCRT opened at $1.53 on Thursday. Alaunos Therapeutics has a 1-year low of $1.48 and a 1-year high of $20.30. The company’s fifty day moving average price is $1.73 and its two-hundred day moving average price is $2.17.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.